DE3688841T2 - Schwache interferondosierung für die erhöhung der impfstoffwirksamkeit. - Google Patents

Schwache interferondosierung für die erhöhung der impfstoffwirksamkeit.

Info

Publication number
DE3688841T2
DE3688841T2 DE87902456T DE3688841T DE3688841T2 DE 3688841 T2 DE3688841 T2 DE 3688841T2 DE 87902456 T DE87902456 T DE 87902456T DE 3688841 T DE3688841 T DE 3688841T DE 3688841 T2 DE3688841 T2 DE 3688841T2
Authority
DE
Germany
Prior art keywords
vaccine effectiveness
increasing vaccine
vaccine
low interferon
interferon dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE87902456T
Other languages
English (en)
Other versions
DE3688841D1 (de
Inventor
Joseph M Cummins Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texas A&M University System
Original Assignee
Texas A&M University System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas A&M University System filed Critical Texas A&M University System
Publication of DE3688841D1 publication Critical patent/DE3688841D1/de
Application granted granted Critical
Publication of DE3688841T2 publication Critical patent/DE3688841T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/811—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE87902456T 1985-12-30 1986-12-22 Schwache interferondosierung für die erhöhung der impfstoffwirksamkeit. Expired - Fee Related DE3688841T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/814,317 US4820514A (en) 1985-12-30 1985-12-30 Low dosage of interferon to enhance vaccine efficiency

Publications (2)

Publication Number Publication Date
DE3688841D1 DE3688841D1 (de) 1993-09-09
DE3688841T2 true DE3688841T2 (de) 1994-01-05

Family

ID=25214702

Family Applications (1)

Application Number Title Priority Date Filing Date
DE87902456T Expired - Fee Related DE3688841T2 (de) 1985-12-30 1986-12-22 Schwache interferondosierung für die erhöhung der impfstoffwirksamkeit.

Country Status (10)

Country Link
US (1) US4820514A (de)
EP (1) EP0253887B1 (de)
AT (1) ATE92332T1 (de)
AU (1) AU608519B2 (de)
CA (1) CA1323564C (de)
DE (1) DE3688841T2 (de)
HK (1) HK25395A (de)
IE (1) IE61707B1 (de)
NZ (1) NZ218825A (de)
WO (1) WO1987004076A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689224A (en) * 1985-10-07 1987-08-25 Neogen Corporation Method for administering vaccines containing equine leukokines and compositions therefor
EP0241725B1 (de) * 1986-03-17 1992-12-09 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Impfstoffe
AU651949B2 (en) * 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
US5578323A (en) * 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US5451410A (en) * 1993-04-22 1995-09-19 Emisphere Technologies, Inc. Modified amino acids for encapsulating active agents
US5270038A (en) * 1992-01-23 1993-12-14 Board Of Regents, The University Of Texas System Tumor necrosis factor receptors on microorganisms
DE69324671D1 (de) * 1992-02-10 1999-06-02 Interferon Sciences Inc Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
US5401516A (en) * 1992-12-21 1995-03-28 Emisphere Technologies, Inc. Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
EP0609739A1 (de) * 1993-02-02 1994-08-10 American Cyanamid Company Methode der Umkehrung der Immunsuppression in Vakzinen
DE69431320T2 (de) * 1993-04-09 2003-04-17 Hayashibara Biochem Lab Verwendung von menschlichem Interferon-d zur Herstellung eines Arzneimittels zur Behandlung von Atemwegserkrankungen in Katzen
NZ332689A (en) 1996-05-09 2000-07-28 Pharma Pacific Pty Ltd Using interferon to treat autoimmune, mycobacterial or neurodegenerative disease
US20030108519A1 (en) * 1996-05-09 2003-06-12 Pharma Pacific Pty Ltd. Therapeutic applications of high dose in terferon
US5972658A (en) * 1996-12-05 1999-10-26 Incyte Pharmaceuticals, Inc. DNA encoding lung growth factor variant
US6436391B1 (en) * 1997-01-31 2002-08-20 Imperial College Of Science, Technology & Medicine Use of interferon (IFN)-α8 and -α14 as vaccine adjuvants
US6660258B1 (en) 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
US20060025348A1 (en) * 1997-05-28 2006-02-02 Pilon Aprile L Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20030008816A1 (en) * 1997-05-28 2003-01-09 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20060281681A1 (en) * 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
US6506385B1 (en) 1998-04-17 2003-01-14 Embrex, Inc. Live vaccines and methods of treatment therewith
US6433144B1 (en) 1999-01-12 2002-08-13 Viragen, Inc. Compositions of highly-purified natural mixtures of type I Interferon derived from leukocytes and methods
IL150109A0 (en) * 1999-12-09 2002-12-01 Chiron Corp Method for administering a cytokine to the central nervous system and the lymphatic system
WO2002060921A2 (en) * 2000-11-09 2002-08-08 Board Of Trustees Of The University Of Illinois Enhancement of immune response to vaccine by interferon alpha
EP1250933A1 (de) * 2001-04-17 2002-10-23 Istituto Superiore di Sanità Impfstoffe mit hochdosiertem Typ I IFN als Adjuvans
JP5230891B2 (ja) * 2001-09-28 2013-07-10 株式会社癌免疫研究所 抗原特異的ｔ細胞の新規な誘導方法
EP1539960B1 (de) * 2002-09-09 2010-04-28 Hanall Pharmaceutical Co., Ltd. Protease-resistente modifizierte interferon alpha polypeptide
EP1951288A2 (de) * 2004-06-12 2008-08-06 Pharma Pacific Pty. Ltd. Verfahren zur erhöhung der immunreaktion auf einen impfstoff
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
EP2303308A4 (de) 2008-05-13 2012-11-07 Clarassance Inc Rekombinanter humaner cc10 und zusammensetzungen dafür zur verwendung bei der behandlung von nasaler rhinitis
NZ599511A (en) 2009-10-15 2014-06-27 Clarassance Inc Recombinant human cc10 protein for treatment of influenza
US9168285B2 (en) 2009-10-15 2015-10-27 Therabron Therapeutics, Inc. Recombinant human CC10 protein for treatment of influenza and ebola
US9642893B2 (en) 2013-07-03 2017-05-09 Joseph Cummins Method for reducing injury and stabilizing muscle using orally administered interferon

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE180737C (de) *
US3906092A (en) * 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
ZA754725B (en) * 1974-08-01 1976-06-30 H Stickl Preparation for the treatment of infectious diseases, method for the manufacture thereof, and its use
DK485977A (da) * 1977-11-01 1979-05-02 Ess Foodeksport Fremgangsmaade til udvinding af et biologisk aktivt materiale fra svineblodfraktioner
US4358376A (en) * 1979-10-29 1982-11-09 Terumo Corporation Apparatus for detoxifying body fluid
DE3122669A1 (de) * 1980-06-12 1982-02-11 Asta-Werke Ag, Chemische Fabrik, 4800 Bielefeld "verfahren zur herstellung von neuen mutanten von herpes simplex-viren typ 1 und typ 2"
US4460574A (en) * 1980-06-16 1984-07-17 Yabrov Alexander A Prophylaxis or treatment of interferon-sensitive diseases
US4429045A (en) * 1980-07-30 1984-01-31 Norden Laboratories, Inc. Rabies virus adapted for growth in swine testicle cell culture
US4462985A (en) * 1980-08-22 1984-07-31 University Of Illinois Foundation Delivery of biologically active components of heterologous species interferon isolates
EP0058192A1 (de) * 1980-08-22 1982-08-25 University of Illinois Foundation Abgabe biologisch aktiver komponenten aus interferon isolierten der heterologischen species
DE3273597D1 (en) * 1981-11-28 1986-11-06 Sunstar Kk Pharmaceutical composition containing interferon in stable state
US4497795A (en) * 1982-12-13 1985-02-05 The Texas A&M University System Method of regulating appetite and efficiency of food utilization employing interferon
US4820515A (en) * 1982-12-13 1989-04-11 Texas A&M University System Method of using interferon in low dosage to regulate appetite and efficiency of food utilization
WO1986003412A1 (en) * 1984-12-06 1986-06-19 David Arthur John Tyrrell Improvements relating to the treatment control and prevention of rhinovirus infections
EP0241725B1 (de) * 1986-03-17 1992-12-09 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Impfstoffe

Also Published As

Publication number Publication date
EP0253887B1 (de) 1993-08-04
ATE92332T1 (de) 1993-08-15
CA1323564C (en) 1993-10-26
IE61707B1 (en) 1994-11-30
DE3688841D1 (de) 1993-09-09
EP0253887A1 (de) 1988-01-27
AU7589587A (en) 1987-07-28
IE863405L (en) 1987-06-30
NZ218825A (en) 1990-06-26
HK25395A (en) 1995-03-03
US4820514A (en) 1989-04-11
AU608519B2 (en) 1991-04-11
WO1987004076A1 (en) 1987-07-16

Similar Documents

Publication Publication Date Title
DE3688841T2 (de) Schwache interferondosierung für die erhöhung der impfstoffwirksamkeit.
FI875533A (fi) Insulinpreparat foer non-parenteral dosering.
ES2106785T3 (es) Medicamentos, su preparacion y empleo como analgesicos y/o antiinflamatorios para seres humanos y animales.
IT8667657A1 (it) Dispositivo erogatore per la somministrazione di un agente benefico all'ambiente d'uso particolarmente per la somministrazione di un agente terapeutico ad un animale ruminante.
MX171191B (es) Composiciones farmaceuticas de glipizida
PT82457A (en) Process for the preparation of pharmaceutical compound with base in phosphonil-methoxy-alkyl-adenines with antiviral activity
MX9203554A (es) Un dispositivo osmotico para administrar doxazosin
GR76810B (de)
ATE229981T1 (de) Glykolisierte cytokine
KR870010871A (ko) 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법
MY101632A (en) Veterinary preparations
DE69706657D1 (de) Natürliches menschliches alpha interferon enthaltende pharmazeutische zusammensetzungen
OA08768A (fr) Traitement du virus su SIDA par l'interféron alpha humain recombinant.
MD157C2 (ro) Produs cu acţiune lactogenă
RU93041496A (ru) γ -РL/ГАММА-ПЛАНТ/-ИНТЕРФЕРОНИНДУЦИРУЮЩЕЕ СРЕДСТВО
RU2004235C1 (ru) Способ профилактики острых респираторных болезней тел т
RU92009266A (ru) Способ повышения молочной продуктивности верблюдиц
IT8521690V0 (it) Struttura perfezionata di siringa per uso sanitario, dotata di dispositivi terminali di protezione, atti a mantenere sterili l'ago e la porzione posteriore della siringa stessa.
RU94022334A (ru) Способ лечения и профилактики инвазионных заболеваний
GB1149313A (en) Improvements relating to therapeutically active hydroxychloroquine salts
UY24191A1 (es) Bolo para administrar una sustancia biologicamente beneficiosa a animales rumiantes
IT1283945B1 (it) Uso dell'interferone alfa naturale umano da cellule linfoblastoidi per la terapia delle epatiti virali, neoplasie e sindromi da
IT1284852B1 (it) Uso dell'interferone alfa naturale umano da cellule leucocitarie per la terapia delle epatiti virali, neoplasie e sindromi da
UA26326C2 (uk) Спосіб лікуваhhя захворюваhь вірусhої та бактеріальhої етіології у людиhи і твариhи та композиція для його реалізації

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee